AI-Measured Thoracic Ascending Aortic Calcification in CAC Scans Predicts Cardiovascular Events: An AI-CVD study in the FHS Offspring Cohort
Abstract Body (Do not enter title and authors here): Introduction/Background The AI-CVD initiative aims to extract opportunistic screening information from coronary artery calcium scans to improve cardiovascular disease prediction. Thoracic aortic calcification (TAC) is a known marker of atherosclerotic burden but remains underutilized in routine coronary artery calcium scan interpretation. Automated quantification of TAC using artificial intelligence may enhance cardiovascular risk prediction, particularly when integrated with conventional risk scores. Research Questions We evaluated whether AI-derived TAC from coronary artery calcium scans independently predicts incident cardiovascular disease in the Framingham Heart Study Offspring cohort. Goals To assess whether automated TAC measured by the AutoTAC component of AI-CVD predicts future cardiovascular events independently of coronary artery calcium and traditional cardiovascular risk factors. Methods Baseline coronary artery calcium scans from 1,002 asymptomatic participants in the Framingham Heart Study Offspring cohort were analyzed using AI-enabled thoracic ascending aortic calcification quantification. TAC scores were categorized as 0, 1–99, 100–299, 300–999, and ≥1000. Cox proportional hazards models estimated hazard ratios for cardiovascular disease across TAC categories using unadjusted, age-adjusted, and fully adjusted models accounting for coronary artery calcium and established risk factors. Results 296 CVD events accrued over 17 years follow-up. In fully adjusted models, compared to participants with zero TAC scores, participants with TAC scores of 100–299 had a hazard ratio of 2.05 (95% CI: 1.19–3.54), those with scores 300–999 had a hazard ratio of 2.29 (95% CI: 1.32–3.97), and those with scores ≥1000 had a hazard ratio of 2.85 (95% CI: 1.66–4.89). Lower categories (1–99) were not statistically significant after adjustment (HR 1.21, 95% CI: 0.73–2.03). The risk of cardiovascular disease increased progressively with higher TAC burden. Conclusion(s) In the FHS Offspring cohort, AI-measured TAC from coronary artery calcium scans was independently associated with future cardiovascular disease events over 17 years of follow-up. These findings support the utility of opportunistic AI-enabled aortic calcification assessment as an adjunct to traditional coronary artery calcium scoring in enhancing long-term risk stratification.
Naghavi, Morteza
( HeartLung Technologies
, Houston
, Texas
, United States
)
Atlas, Kyle
( HeartLung Technologies
, Houston
, Texas
, United States
)
Zhang, Chenyu
( HeartLung Technologies
, Houston
, Texas
, United States
)
Reeves, Anthony
( Cornell University
, Ithaca
, New York
, United States
)
Atlas, Thomas
( Tustin Teleradiology
, Tustin
, California
, United States
)
Wasserthal, Jakob
( University Basel
, Basel
, Switzerland
)
Wong, Nathan
( University of California, Irvine
, Irvine
, California
, United States
)
Benjamin, Emelia
( Boston University School Medicine
, Brookline
, Massachusetts
, United States
)
Levy, Daniel
( NHLBI-FRAMINGHAM HEART STUDY
, Newton Highlands
, Massachusetts
, United States
)
Author Disclosures:
Morteza Naghavi:DO have relevant financial relationships
;
Ownership Interest:HeartLung.AI:Active (exists now)
| Kyle Atlas:No Answer
| Chenyu Zhang:DO have relevant financial relationships
;
Employee:HeartLung Corporation:Active (exists now)
; Individual Stocks/Stock Options:HeartLung Corporation:Active (exists now)
| Anthony Reeves:DO have relevant financial relationships
;
Individual Stocks/Stock Options:HeartLung Technologies:Active (exists now)
| Thomas Atlas:No Answer
| Jakob Wasserthal:DO have relevant financial relationships
;
Consultant:HeartLungAi:Active (exists now)
| Nathan Wong:DO have relevant financial relationships
;
Research Funding (PI or named investigator):Amgen, Novartis, Ionis:Active (exists now)
; Consultant:Ionis:Past (completed)
; Speaker:Novartis:Past (completed)
; Consultant:Heart Lung, Amgen, Novartis:Active (exists now)
; Research Funding (PI or named investigator):Novo Nordisk, Regeneron:Past (completed)
| Emelia Benjamin:DO NOT have relevant financial relationships
| Daniel Levy:DO have relevant financial relationships
;
Other (please indicate in the box next to the company name):Elsevier Publishing:Active (exists now)